About GoBroad Healthcare Group
China's Leader in CAR-T Therapy, Bone Marrow Transplant and Cancer TreatmentsGoBroad Healthcare Group
National leader in adoptive cell therapy, immunotherapy and targeted therapy.
What sets it apart is access to treatments simply not available in most countries, including CAR-T cell therapy, haematopoietic stem cell transplantation, and gene therapy for conditions such as thalassemia and sickle cell disease.
Those outcomes speak clearly. GoBroad's CAR-T programme achieves a complete remission rate of over 90% in relapsed or refractory B-cell leukaemia, and the thalassemia transplant team holds the world's highest published survival rate at 97%.
GoBroad has treated international patients from 12+ countries, achieving a 95% patient satisfaction rate. Medical visa guidance, airport transfers, language interpreters, and post-discharge follow-up are all handled for you.
Your journey to better health at GoBroad Healthcare Group starts here
We are the Official Information & Representative Office for GoBroad Healthcare Group, helping to coordinate all medical treatments and check-ups for FREE.Explore GoBroad Healthcare Group Locations
GoBroad Healthcare Group's Accreditation & Awards
- ISO 15189 Clinical Laboratory Accreditation
- CAP Certification (College of American Pathologists )
- Phase I Clinical Trial Institution Registration
- Certified Centre for Bone Marrow Transplantation in China
- Member of Shanghai Ruijin Hospital Blood Disease Medical Association
- Teaching Hospital Designation- Beijing University of Chinese Medicine
- 33 Research Presentations at ASH Annual Meeting- American Society of Hematology - 2025
- ASH Abstract Achievement Award- American Society of Hematology — 2025
Gallery
Frequently Asked Questions
Have a question? Our support team is here to guide you through each step of your treatment journey with personal care and attention.How do I contact GoBroad's international patient support team?
Appointments, medical consultations, and treatment planning at GoBroad Healthcare Group in China are coordinated through the International Patient Care team at My1Health, which assists international patients before they travel.
You can contact the team through the following channels:
- WhatsApp: +1 718 550 0880
- Telephone: +1 718 550 0880
- Email: [email protected]
Support includes arranging in-person appointments, online video consultations, second medical opinions, and treatment planning, connecting international patients directly with GoBroad's specialist doctors without unnecessary delays.
Why do international patients choose GoBroad Healthcare Group for blood and solid cancer treatment in China?
GoBroad Healthcare Group is China's most research-active hospital network for blood cancers and complex solid tumours, with some of the best clinical outcomes globlly.
For patients who have relapsed after standard treatment at home, GoBroad offers access to CAR-T cell therapy, haematopoietic stem cell transplantation, gene therapy, and investigator-initiated trials for therapies not yet commercially available elsewhere.
Key reasons patients travel to GoBroad:
- CAR-T complete remission rate exceeding 90% for relapsed or refractory B-cell leukaemia
- 4,000+ HSCT procedures completed, with outcomes that exceed international benchmarks
- 97% thalassemia transplant success rate, the highest published globally
What blood cancers and haematological conditions does GoBroad treat?
GoBroad Healthcare Group treats haematological malignancies and disorders, with particular depth in relapsed and refractory cases.
Conditions treated include:
- Acute lymphoblastic leukaemia (ALL)
- Acute myeloid leukaemia (AML)
- Chronic myeloid and lymphocytic leukaemia
- Hodgkin and non-Hodgkin lymphoma
For patients who have failed standard therapy, GoBroad's CAR-T cell therapy, TDH transplantation, and gene therapy programmes offer treatment options that are not widely available outside China.
Does GoBroad Healthcare Group offer CAR-T cell therapy for international patients?
Yes. GoBroad was among the first hospitals in China to build a systematic CAR-T programme and has now performed several thousand treatments across its network.
International patients can access both commercial CAR-T products and investigator-initiated trial protocols, including multi-target therapies that are years ahead of commercial licensing.
For relapsed or refractory B-cell leukaemia, GoBroad's CD19 CAR-T programme achieves a complete remission rate of over 90%.
Active CAR-T programmes also cover lymphoma, multiple myeloma, T-cell malignancies, autoimmune diseases, and selected solid tumours, including digestive tract cancers using Claudin18.2 CAR-T.
Does GoBroad treat children with blood cancer or thalassemia?
GoBroad Healthcare Group has one of China's largest and most recognised paediatric haematology programmes.
The Nanfang-Chunfu Children's Institute of Hematology in Guangdong, led by Professor Chunfu Li in strategic cooperation with Mayo Clinic, performed 1,223 paediatric HSCTs between July 2018 and January 2024.
Paediatric transplants at GoBroad cover children from as young as one month of age up to 75 years across its adult and paediatric facilities.
The team treats ALL, AML, juvenile myelomonocytic leukaemia (JMML), thalassemia in children, and rare blood disorders, with an overall survival rate of 97.84% for paediatric thalassemia patients published in Blood and Leukemia.
What international patient services are available at GoBroad Healthcare Group?
GoBroad's International Patient Service Centre handles every stage of the medical travel process, from the first enquiry through to post-discharge follow-up once you are home.
Services include:
- Online or in-person specialist consultations before and after travel
- Second medical opinions for complex or high-risk diagnoses
- Medical visa documentation support
- Airport transfers and local transport coordination in Beijing, Shanghai, or Guangzhou
- Accommodation booking for patients and family members
- A personalised treatment itinerary prepared before departure
- Multilingual interpreter support throughout the hospital stay
- Secure digital access to treatment reports and diagnostic results after returning home
Where are GoBroad's hospitals located and how do international patients get there?
GoBroad Healthcare Group operates 8 hospitals across 3 of China's major cities: Beijing, Shanghai, and Guangzhou.
Each location is accessible from major international airports, with dedicated airport transfer services coordinated by the international patient team.
Key locations:
- Beijing GoBroad Hospital: Changping Life Science Park, 40 minutes from Beijing Capital International Airport
- Beijing GoBroad Boren Hospital: Fengtai District, 35 minutes from Beijing Capital International Airport
- Shanghai GoBroad Cancer Hospital: Pudong New Area, Shanghai, accessible from Pudong International Airport
- Guangdong (Dongguan) Chunfu Institute: Dongcheng District, Dongguan, serving the Pearl River Delta region
All airport transfers, accommodation arrangements, and hospital visit logistics are managed by the international patient team before departure.
